Corifollitropin Alfa
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Corifollitropin Alfa
- Pharmacist Assessment Report
- Corifollitropin alfa: long-acting recombinant FSH agonist → gastroduodenitis (gastroduodenitis)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Corifollitropin alfa: long-acting recombinant FSH agonist → gastroduodenitis (gastroduodenitis)
One-Sentence Summary
Corifollitropin alfa is a long-acting recombinant follicle-stimulating hormone (FSH) agonist used for controlled ovarian stimulation. The TxGNN model predicts it may be relevant to gastroduodenitis, but no clinical trials and no publications currently support this direction, so the prediction rests on computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | gastroduodenitis |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on what is known, corifollitropin alfa is an FSH-beta chain fused with the C-terminal peptide of hCG, which gives it a long duration of action at the FSH receptor.
No plausible mechanistic link between FSH receptor stimulation and gastroduodenal inflammation has been identified. The high score (0.9965) is a model output only and probably reflects patterns in the underlying network rather than biology. This prediction should be regarded as a hypothesis with no biological support at present.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 5816D | Elonva | Solution for injection 100 micrograms in 0.5 mL single dose pre-filled syringe | Not recorded in the local data |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature, no identifiable mechanistic link, and sits at evidence level L5 (model prediction only). Ovarian stimulation also carries its own safety considerations that would need to be weighed in any new setting.
To proceed, the following is needed:
- Mechanism of action data and a biologically plausible hypothesis linking FSH receptor agonism to gastroduodenal disease
- Preclinical or observational evidence that directly studies gastroduodenitis
- Warnings and contraindications from the TGA-approved Product Information for safety screening
- Assessment of route and population suitability for the proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.